FDA advisory panel recommends approval of Gardasil to prevent genital warts in young men Bonus Lobbying Victory: European regulators give Gardasil nod for use in women up to the age of 45 Last week was good to Merck's hopes for an improved bottom line next quarter. It was a … [Read more...] about FDA Gifts Merck’s Garasil With Broader Market Access
The product information for Gardasil® has been updated to include the clinical efficacy and safety of the vaccine for women up to 45 years of age. - The product information of the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® has been updated to include the … [Read more...] about MERCK Press Release Touting Clinical Efficacy of Gardasil for Mature Women
FDA experts back Merck's application to extend the use of Gardasil to males In twin votes likely to add considerable force to U.S. marketing efforts for HPV vaccines, an FDA expert panel has voted to back GlaxoSmithKline's long delayed application to market its HPV vaccine … [Read more...] about Cervarix On Track for FDA Approval, Garasil to Have Expanded Use
FDA once again backs HPV vaccines as panel prepares to vote As an expert FDA panel prepared to meet this week to review new applications to market Cervarix to prevent cervical cancer in women and expand the use of Gardasil to prevent genital warts in males, both companies got … [Read more...] about FDA Staffers Stick With Their HPV Vaccine Position
Fresh controversies are heating up over the marketing of products to prevent cervical cancer The U.S. Food & Drug Administration is gearing up to make critical decisions about two controversial vaccines. On Sept. 9 an FDA advisory committee will consider whether Merck … [Read more...] about Is Merck Overselling a Cancer Vaccine?